Format

Send to

Choose Destination
Am J Hematol. 2018 Feb;93(2):E49-E52. doi: 10.1002/ajh.24980. Epub 2017 Dec 4.

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Author information

1
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
2
Department of Medicine, University of Washington, Seattle, Washington.
3
Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
4
SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
5
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
6
Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Madison.
7
SWOG Operations, San Antonio, Texas.
8
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
9
Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida.
10
Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
11
Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University, Winston-Salem, North Carolina.
12
Department of Medicine, Queen's University, Kingston, Ontario, Canada.
13
Jewish General Hospital, Montreal, Quebec, Canada.
14
Moffitt Cancer Center, Tampa, Florida.
15
Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada.
16
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
17
Adult Leukemia Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
18
Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
PMID:
29164656
PMCID:
PMC5760282
[Available on 2019-02-01]
DOI:
10.1002/ajh.24980
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center